Reduced inflammation at the site of myocardial infarction and improved heart function demonstrated. Novel therapy to modulate immune response with apoptotic cell-derived nanovesicles
September 14, 2023
Myocardial Infarction, the Number One Cause of Sudden Death, May be Treated by Modulating the Immune Response
September 14, 2023 — Myocardial infarction, the number one cause of sudden death in adults and the number two cause of…
Read More
University Hospitals Harrington Heart & Vascular Institute first to adopt technology in U.S.
September 13, 2023
New Study Confirms HeartFlow FFRCT Leads to Improved Patient Outcomes
September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington…
Read More
Socioeconomic status (education, income, employment status and health insurance) appears to be an uneven predictor of heart health with white adults benefitting the most in comparison to Black, Hispanic and Asian Americans
September 13, 2023
Ohio State Study Shows Socioeconomic Status May Be An Uneven Predictor of Heart Health
September 13, 2023 — Socioeconomic status (education, income, employment status and health insurance) appears to be an…
Read More
The Smidt Heart Institute at Cedars-Sinai has earned a prestigious designation for its excellence in adult and pediatric extracorporeal membrane oxygenation
September 13, 2023
Smidt Heart Institute’s ECMO Expertise Awarded
September 13, 2023 — The Smidt Heart Institute at Cedars-Sinai has earned a prestigious designation for its excellence…
Read More
The analysis of the health records found that, on average, participants’ systolic blood pressure increased by up to 1.7 mm Hg in the winter months compared to the summer months
September 13, 2023
Study from AHA Hypertension Scientific Sessions Reports on Cold Weather’s Impact on Treating High Blood Pressure
September 13, 2023 — Blood pressure among patients diagnosed with hypertension appeared to slightly increase, and rates…
Read More
Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN).
September 12, 2023
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions
September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of…
Read More
Interim results from SOTERIA open-label extension study represent longest safety and efficacy analysis of sotatercept to date
September 12, 2023
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
September 12, 2023 — Merck announced new analyses from studies of sotatercept, Merck’s novel investigational activin…
Read More
The global interventional cardiology device market is driven by the number of procedures performed across the globe
By Emily Gilbert and Kamran Zamanian, PhD
September 12, 2023
The New Interventional Cardiology Market
The global interventional cardiology device market is driven by the number of procedures performed across the globe.…
Read More
UCLA-led research finds that among adult congenital heart disease (CHD) transplant recipients, single-ventricle physiology correlated with higher short-term mortality
September 12, 2023
UCLA Research Suggests that Heart Transplantation is Safer for Adults with Single-ventricle CHD than Previously Thought
September 12, 2023 — UCLA-led research finds that among adult congenital heart disease (CHD) transplant recipients,…
Read More
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL
September 12, 2023
American College of Cardiology Program to Increase Cholesterol Screenings
September 12, 2023 — The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is…
Read More
Premier cardiovascular digital health experience continues cultivating a community to examine and solve for future complex healthcare needs
September 11, 2023
HRX 2023 Conference Propelling the Future of Digital Health
September 11, 2023 — The Heart Rhythm Society (HRS) is gearing up for its second annual HRX event, bringing…
Read More
The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR
September 11, 2023
MedAlliance Announces Enrollment of First Patient in SELUTION SLR LOVE-DEB Coronary Study
September 11, 2023 — The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease…
Read More
Regulatory and quality leader brings decades of global SaMD experience to guide leading AI-powered cardiovascular diagnostic company through growth and expansion
September 11, 2023
Elucid Appoints Windi Hary to Lead Regulatory Affairs and Quality Management
September 11, 2023 — Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging…
Read More
the Company is exploring development of a new Phase III clinical trial protocol
September 08, 2023
BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs
September 8, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of…
Read More
MPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023
September 08, 2023
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
September 8, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing…
Read More
Patients of African ancestry with dilated cardiomyopathy (DCM) are less likely to have clinically actionable variants in DCM genes than those of European ancestry
September 08, 2023
Study Highlights Need for Diversity in Clinical Trials to Better Understand, Treat Inherited Heart Muscle Disease
September 8, 2023 — Patients of African ancestry with dilated cardiomyopathy (DCM) are less likely to have clinically…
Read More
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety
September 07, 2023
Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX Pro Left Atrial Appendage Closure Device
September 7, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration approval…
Read More
Recipient of the Harry Goldblatt Award for New Investigators from the American Heart Association’s 2023 Hypertension Council
September 07, 2023
Faulkner to be Honored by American Heart Association
September 7, 2023 —Jessica Faulkner, PhD, a physiologist whose research is focused on sex differences in cardiovascular…
Read More
Exclusive agreement for AI algorithms to accelerate earlier detection of cardiac amyloidosis and pulmonary hypertension
September 07, 2023
Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms
September 7, 2023 — Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, announced that…
Read More
Vektor Medical has announced the release of a series of software enhancements to its AI-based non-invasive solution, vMap, which were designed to improve ablation outcomes and procedural efficiencies.
September 07, 2023
Vektor Medical Announces Enhanced AI-based vMap for Improved Cardiac Ablation Outcomes, Non-Invasive Mapping of Cardiac Arrhythmias
September 7, 2023 — Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now